Clinical Trials Logo

Cannabis Use clinical trials

View clinical trials related to Cannabis Use.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06322303 Active, not recruiting - Cannabis Use Clinical Trials

Effect of Cannabidiol (CBD) on Vision and Driving

Start date: February 1, 2023
Phase: Early Phase 1
Study type: Interventional

The use of cannabis with ∆9-tetrahydrocannabinol (THC) content has been shown to have negative effects on vision and driving. The use of other cannabinoids, such as cannabidiol (CBD), which is not attributed with a psychoactive effect, is increasing significantly. This project aims to investigate whether consuming CBD can negatively affect visual function by assessing a wide range of visual parameters and whether these changes may pose a risk for everyday activities such as driving.

NCT ID: NCT05824754 Active, not recruiting - Cannabis Use Clinical Trials

An App to Reduce Cannabis Use Among Emerging Adults

Start date: February 21, 2024
Phase: N/A
Study type: Interventional

This study is being completed to pilot prevention methods to promote wellness and reduce risky behaviors, including the use of substances such as cannabis. This study will help researchers learn about ways of delivering this information that is both appealing and helpful to young adults who use mobile apps.

NCT ID: NCT05663346 Active, not recruiting - Nurse's Role Clinical Trials

Cannabis and Cancer, an Online Training for Oncology Nurses

Start date: January 4, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the preliminary effects and impacts of a digital educational intervention to support nurses' professional practice regarding safe cannabis use by young adults (18-39 years) diagnosed with cancer.

NCT ID: NCT05273567 Active, not recruiting - Cannabis Use Clinical Trials

A Trial of Guanfacine-er for Cannabis Use Disorder

Start date: June 1, 2022
Phase: Phase 2
Study type: Interventional

The primary purpose of this study is to investigate the effect of guanfacine-ER on reductions in cannabis use and explore its effects on impulsivity and withdrawal through a hybrid in-person and virtual trial of treatment-seeking individuals with Cannabis Use Disorder (CUD), and assessing the feasibility of the virtual components of the study.

NCT ID: NCT04374773 Active, not recruiting - Pregnancy Related Clinical Trials

Effects of Pregnancy-associated Hormones on THC Metabolism in Women

PrECEPT
Start date: October 19, 2020
Phase: Phase 4
Study type: Interventional

Cannabis use is prevalent among pregnant women, but the effects of use on both the developing fetus and pregnant woman are unknown. Importantly, drug exposure could be influenced by the impact of pregnancy-associated hormones on the metabolism of tetrahydrocannabinol (THC), the main psychoactive component of cannabis. The goal of this study is to determine whether cortisol and estradiol - hormones that rise dramatically during pregnancy - increase the clearance of dronabinol (THC) in reproductive age women to simulate the pregnant state. The collected data will then be used to predict the time course and magnitude of changes in THC metabolism in pregnant women, particularly with gradually increasing estradiol and cortisol concentrations that evolve over the course of pregnancy. The overall objective of this study is to better understand the effects of THC use during pregnancy on the health of the pregnant woman and developing fetus.

NCT ID: NCT03581058 Active, not recruiting - Cannabis Use Clinical Trials

Neural Correlates of Driving and Cannabis

Start date: August 8, 2018
Phase: Phase 1
Study type: Interventional

Driving is a set of complex tasks and requires use of multiple cognitive domains, including attention, planning, and memory. In laboratory studies, the main psychoactive component in cannabis, delta-9-tetrahydrocannabinol (THC), was shown to impair short-term memory, attention, reaction time, tracking, and coordination, resulting, for instance, in significantly more deviations from the lane and increased break latency. Surveys and epidemiological studies suggest that cannabis consumption is associated with increased risks of collision. The current study aims to evaluate individual driving behavior and performance on various neurocognitive tests and their correlated neural networks while under the influence of cannabis and while sober. The investigators will use the STISIM driving simulator, which is fully MRI compatible, to study brain activation, while participants are performing various driving maneuvers. The goals of the study are: 1. identify driving performance and patterns in brain activation associated with cannabis exposure and compare them to brain patterns of the same participants while sober; 2. compare participant's performance on cognitive tasks while under the influence of cannabis and sober; 3. look for correlations between concentration of cannabinoids in the participants' blood and their driving performance and performance on cognitive tasks; 4. correlate demographic variables and personal history (e.g. tolerance to drug) with performance and brain activation while driving under the influence of cannabis.

NCT ID: NCT03379857 Active, not recruiting - Stroke Clinical Trials

Prevalence of Strokes Secondary to a Reversible Cerebral Vasoconstriction Attributable to Cannabis Consumption in Young Subjects (≤ 45 Years) Hospitalized for an Ischaemic Stroke

CANNASTROKE
Start date: January 11, 2018
Phase: N/A
Study type: Interventional

Incidence of strokes has increased these last 20 years in young population. This rise could be linked to alcohol, tobacco or drug use like cannabis. Cannabis has previously been descripted as a potential factor of reversible vasoconstriction. The main objective is to show that an exhaustive assessment of a stroke facing a young person frequently lead to a diagnostic of reversible vasoconstriction due to cannabis use. Evaluation will focus on prevalence of strokes secondary to a reversible vasoconstriction attributable to cannabis in young subjects. There's a real public healthcare interest in terms of primary and secondary prevention to evaluate the role of cannabis as a risk factor of stroke in young population.

NCT ID: NCT02102113 Active, not recruiting - Schizophrenia Clinical Trials

Probing the Cannabinoid System in Individuals With a Family History of Psychosis

Start date: January 2014
Phase: Early Phase 1
Study type: Interventional

The overall purpose of this study is to determine whether a family history of psychosis is associated with an altered cannabinoid system. This will be tested by studying individuals with and without a family history of psychosis and comparing their responses to delta 9-tetrahydrocannabinol (THC), a probe of the cannabinoid system. We hypothesize, that compared to controls with no family history of psychoses, individuals with a family history of psychoses will have an altered response to THC.